INDPNasdaq

Indaptus Therapeutics, Inc.

Healthcare·Oncology·Phase 1·New York, NY, United States
Oncology

Indaptus Therapeutics, Inc. (INDP): 2 pipeline candidates · ~1 mo cash runway · 1 clinical trial. Updated within the last hour.

4.9/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway0.2

0.7 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider Signal3.6

0 buys · 2 sells (180d)

A transparent, data-derived signal for Indaptus Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$479.6M

Cash

$1.5M

Quarterly Burn

$7.0M

Runway

0.7 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (2 candidates)

DrugPhase
decoy20Phase 1/Phase 2
tislelizumabPhase 1/Phase 2

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

3

Total value held

$125K

HolderSharesValue
citadel advisors llc39,018$71K
geode capital management, llc27,007$49K
morgan stanley2,697$5K
1 clinical trial·CEO: Mr. Junyi Dai

Frequently asked questions

How many drug candidates are in Indaptus Therapeutics, Inc.'s pipeline?

Indaptus Therapeutics, Inc. (INDP) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Indaptus Therapeutics, Inc.'s lead drug candidate?

Indaptus Therapeutics, Inc.'s most advanced tracked candidate is decoy20 (Phase 1/Phase 2) for Solid Tumor, Adult.

What is Indaptus Therapeutics, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Indaptus Therapeutics, Inc. has approximately 0.7 months of cash runway.

What is Indaptus Therapeutics, Inc.'s market capitalization?

Indaptus Therapeutics, Inc.'s market capitalization is approximately $479.6M.

Who is the CEO of Indaptus Therapeutics, Inc.?

Mr. Junyi Dai is the chief executive officer of Indaptus Therapeutics, Inc. (INDP).

Get the full picture on Indaptus Therapeutics, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.